冷储存血小板用于战创伤的安全性及可行性分析
该研究基于国防部创伤登记处和武装部队血液计划数据库,纳入2016年1月1日至2020年2月29日间接受室温储存血小板(RSPs)或RSPs联合冷储存血小板(RSPs-CSPs)的274例战创伤伤员,比较两组特征。结果显示两组生存率无差异(RSPs 88.5% vs RSPs-CSPs 86.7%,p=0.645),不良事件相似;RSPs-CSPs组接受血制品更多,大规模输血比例更高(53.5% vs 33.5%,p=0.001)。logistic回归显示使用RSPs-CSPs与死亡率无关,校正OR 0.96(p>0.9,95%CI 0.41-2.25)。作者认为鉴于安全性和后勤可行性,结果支持继续在军事环境中使用CSPs并进一步研究优化复苏策略。
要点
- 战创伤伤员中,接受RSPs-CSPs者生存率86.7%,接受RSPs者88.5%,两组无差异(p=0.645)。
- 校正后使用RSPs-CSPs与死亡率无关,校正OR 0.96(p>0.9,95%CI 0.41-2.25)。
- RSPs-CSPs组大规模输血比例高于RSPs组(53.5% vs 33.5%,p=0.001),接受血制品更多。
- 两组不良事件相似;作者认为结果支持继续在军事环境中使用CSPs。
适用人群与场景
- 2016年1月1日至2020年2月29日期间在战场接受室温储存血小板(RSPs)或RSPs联合冷储存血小板(RSPs-CSPs)的战创伤伤员,共274例;男性97.1%,平均年龄31.7岁,损伤严重度评分中位数22。
研究设计与关键结果
- 研究类型为安全性分析,数据来自国防部创伤登记处和武装部队血液计划数据库;共274例,131例(47.8%)接受RSPs,143例(52.2%)接受RSPs-CSPs。
- 生存率:RSPs组88.5% vs RSPs-CSPs组86.7%,p=0.645。
- RSPs-CSPs组接受血制品更多,大规模输血比例高于RSPs组(53.5% vs 33.5%,p=0.001)。
- 两组不良事件相似。
- logistic回归显示使用RSPs-CSPs与死亡率无关,校正OR 0.96(p>0.9,95%CI 0.41-2.25)。
证据类型、等级与局限
- 证据类型:治疗/护理管理类安全性分析,证据等级Level IV。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,鉴于安全性和后勤可行性,结果支持继续在军事环境中使用CSPs,并进一步研究如何优化复苏策略。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Damage-control resuscitation has come full circle, with the use of whole blood and balanced components. Lack of platelet availability may limit effective damage-control resuscitation. Platelets are typically stored and transfused at room temperature and have a short shelf-life, while cold-stored platelets (CSPs) have the advantage of a longer shelf-life. The US military introduced CSPs into the battlefield surgical environment in 2016. This study is a safety analysis for the use of CSPs in battlefield trauma.
METHODS: The Department of Defense Trauma Registry and Armed Services Blood Program databases were queried to identify casualties who received room-temperature-stored platelets (RSPs) or both RSPs and CSPs between January 1, 2016, and February 29, 2020. Characteristics of recipients of RSPs and RSPs-CSPs were compared and analyzed.
RESULTS: A total of 274 patients were identified; 131 (47.8%) received RSPs and 143 (52.2%) received RSPs-CSPs. The casualties were mostly male (97.1%), similar in age (31.7 years), with a median Injury Severity Score of 22. There was no difference in survival for recipients of RSPs (88.5%) versus RSPs-CSPs (86.7%; p = 0.645). Adverse events were similar between the two cohorts. Blood products received were higher in the RSPs-CSPs cohort compared with the RSPs cohort. The RSPs-CSPs cohort had more massive transfusion (53.5% vs. 33.5%, p = 0.001). A logistic regression model demonstrated that use of RSPs-CSPs was not associated with mortality, with an adjusted odds ratio of 0.96 (p > 0.9; 95% confidence interval, 0.41-2.25).
CONCLUSION: In this safety analysis of RSPs-CSPs compared with RSPs in a combat setting, survival was similar between the two groups. Given the safety and logistical feasibility, the results support continued use of CSPs in military environments and further research into how to optimize resuscitation strategies.
LEVEL OF EVIDENCE: Therapeutic/Care Management; Level IV.
参考来源
- Fisher AD, Stallings JD, Schauer SG, et al. A safety and feasibility analysis on the use of cold-stored platelets in combat trauma. J Trauma Acute Care Surg. 2024. PMID: 39049142. doi:10.1097/TA.0000000000004334
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。